1
/
of
1
Elabscience
SKU:PKSH033858
Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-mFc)
Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-mFc)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC), a cutting-edge product designed to revolutionize the field of immunology. This meticulously engineered ligand, derived from human CD27, offers unparalleled potential in the realm of immune system modulation.
Crafted with utmost precision, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) showcases remarkable efficacy in stimulating the CD27 receptor, thereby activating T cells and promoting their proliferation. This unique ligand possesses the ability to enhance the immune response, making it an invaluable tool for researchers and clinicians alike.
The Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) is manufactured using state-of-the-art recombinant DNA technology, ensuring exceptional purity and consistency. Its high bioactivity and stability make it an ideal candidate for a wide range of applications, including immunotherapy, vaccine development, and cancer research.
With its remarkable potential to modulate immune responses, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) holds promise in the treatment of various diseases, such as autoimmune disorders, infectious diseases, and cancer. Its ability to activate T cells and promote their survival makes it an indispensable asset in the pursuit of novel therapeutic interventions.
In summary, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) represents a groundbreaking advancement in the field of immunology. Its exceptional bioactivity, purity, and stability make it an indispensable tool for researchers and clinicians seeking to unravel the complexities of the immune system and develop innovative therapeutic strategies. Embrace the future of immunological research with the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC).
Crafted with utmost precision, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) showcases remarkable efficacy in stimulating the CD27 receptor, thereby activating T cells and promoting their proliferation. This unique ligand possesses the ability to enhance the immune response, making it an invaluable tool for researchers and clinicians alike.
The Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) is manufactured using state-of-the-art recombinant DNA technology, ensuring exceptional purity and consistency. Its high bioactivity and stability make it an ideal candidate for a wide range of applications, including immunotherapy, vaccine development, and cancer research.
With its remarkable potential to modulate immune responses, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) holds promise in the treatment of various diseases, such as autoimmune disorders, infectious diseases, and cancer. Its ability to activate T cells and promote their survival makes it an indispensable asset in the pursuit of novel therapeutic interventions.
In summary, the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC) represents a groundbreaking advancement in the field of immunology. Its exceptional bioactivity, purity, and stability make it an indispensable tool for researchers and clinicians seeking to unravel the complexities of the immune system and develop innovative therapeutic strategies. Embrace the future of immunological research with the Recombinant Human CD27 Ligand/TNFSF7/CD70 (C-MFC).
Share
